All In Biotech

Drug Trial Radar · NCT06644768

A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

A Multicenter, Randomized, Open-Label, Phase 1b/2 Trial Of Valemetostat Tosylate Plus Pembrolizumab Vs Pembrolizumab Alone in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 With Tumor Proportion Score ≥50% Without Actionable Genomic Alterations

Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 137 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

137

Planned (sponsor's estimate)

Start

Oct 30, 2024

Primary completion

Mar 30, 2028

Study completion Apr 30, 2030

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Oct 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in First-line NSCLC Without Actionable Genomic Alterations

Conditions

  • Non-small Cell Lung Cancer
  • Lung Cancer

Interventions

  • valemetostat tosylateDrug

    Valemetostat will be administered orally once daily until RP2D of valemetostat is determined.

  • pembrolizumabDrug

    One IV infusion Q3W on D1 of each 21-day cycle for a maximum of 35 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b: Number of Participants with Dose-Limiting ToxicitiesTime frame: From day of first dose on Day 1 to Day 21 in Cycle 1 (21 days), or before the administration of Cycle 2, up to 24 days
  2. Phase 1b: Number of Participants with Treatment-Emergent Adverse EventsTime frame: From date of first dose to 30 days after last dose, up to approximately 31 months
  3. Phase 2: Progression-Free Survival by BICRTime frame: From date of randomization to the date of radiographic disease progression, or death from any cause, whichever occurs first, up to approximately 31 months

Locations

35 sites in 5 countries. Site status is shown where the registry gives one.

  • University of California San Diego (Ucsd)-Moores Cancer Center

    La Jolla, California

  • California Research Institute

    Los Angeles, California

  • Valkyrie Clinical Trials

    Los Angeles, California

  • Mayo Clinic Hospital

    Jacksonville, Florida

  • BRCR Global

    Plantation, Florida

  • University of Kentucky Medical Center

    Lexington, Kentucky

  • Pikeville Medical Center

    Pikeville, Kentucky

  • Mayo Clinic - Rochester

    Rochester, Minnesota

  • Columbia University Irving Medical Center

    New York, New York

  • Thomas Jefferson University, Sidney Kimmel Cancer Center

    Philadelphia, Pennsylvania

  • Virginia Cancer Specialist

    Fairfax, Virginia

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina

  • Instituto Alexander Fleming

    Buenos Aires, Argentina

  • Sanatorio Allende

    Córdoba, Argentina

  • Fundacion Ars Medica

    N Salvador de Jujuy, Argentina

  • Instituto Medico de La Fundacion Estudios Clinicos

    Rosario, Argentina

  • Clinica Viedma S.A.

    Viedma, Argentina

  • Centro de Pesquisas Clinica Reichow

    Blumenau, Brazil

  • Clínica de Neoplasias Litoral Ltda.

    ItajaĂ-, Brazil

  • CINPAM Centro Integrado De Pesquisa Da Amazonia

    Manaus, Brazil

  • Liga Norte-Rio-Grandense Contra o Câncer

    Natal, Brazil

  • Hospital Nossa Senhora da Conceicao

    Porto Alegre, Brazil

  • Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto

    Sao Jose Rio Preto, Brazil

  • Jilin Cancer Hospital

    Changchun, China

  • Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine

    Hangzhou, China

  • Harbin Medical University Cancer Hospital

    Harbin, China

  • Jiamusi Cancer Hospital

    Jiamusi, China

  • Shanghai East Hospital

    Shanghai, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tiyuan, China

  • Henan Cancer Hospital

    Zhengzhou, China

  • Kyushu University Hospital

    Fukuoka, Japan

  • National Cancer Center Hospital East

    Kashiwa, Japan

  • Cancer Institute Hospital of JFCR

    Kōtoku, Japan

  • NHO Nagoya Medical Center

    Nagoya, Japan

  • Kitasato University Hospital

    Sagamihara-shi, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.